The phase 2 LuminICE study shows potential for the AFM13/AB-101 combination in treating patients with relapsed or refractory CD30-positive lymphoma.
Rylan DeStefano
Advertisement
Articles by Rylan DeStefano
Future research may focus on the relationship between neoadjuvant chemotherapy regimens, pathologic complete response, and whole transcriptome changes in patients with hormone receptor–positive, HER2-negative early-stage breast cancer.
Advertisement
Latest Updated Articles
Investigators Will Test Efficacy of AFM13 Plus AB-101 in Hodgkin LymphomaPublished: December 15th 2023 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss
2
Porustobart/Tislelizumab Elicits Responses in MSS Metastatic Colorectal Cancer
3
Classifying High-Risk Patients With NDMM
4
Unraveling the Complexities of Proximal-Type Epithelioid Sarcoma of the Vulva
5
